Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H1 2018 - Product Image

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H1 2018

  • ID: 4464899
  • Report
  • 79 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Aevi Genomic Medicine Inc
  • Bristol-Myers Squibb Co
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Heptares Therapeutics Ltd
  • MORE
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H1 2018

Summary:

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 25 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2018, outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Musculoskeletal Disorders which include indications Anxiety Disorders, Depression, Schizophrenia, Autism, Cognitive Impairment Associated With Schizophrenia (CIAS), Drug-Induced Dyskinesia, Dyskinesia, Fragile X Syndrome, Major Depressive Disorder, Alcohol Addiction, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Cognitive Impairment, DiGeorge Syndrome, Generalized Anxiety Disorder (GAD), Mania, Neurology, Opium (Opioid) Addiction, Pain, Parkinson's Disease, Pervasive Developmental Disorder (PDD), Rett Syndrome and Spasmodic Torticollis.

Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
  • The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Aevi Genomic Medicine Inc
  • Bristol-Myers Squibb Co
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Heptares Therapeutics Ltd
  • MORE
Introduction

The Publisher's Report Coverage

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Aevi Genomic Medicine Inc

Bristol-Myers Squibb Co

Eisai Co Ltd

Eli Lilly and Co

Heptares Therapeutics Ltd

Johnson & Johnson

Merz Pharma GmbH & Co KgaA

Novartis AG

Richter Gedeon Nyrt

Sumitomo Dainippon Pharma Co Ltd

Toray Industries Inc

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles

alloswitch-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-952048 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-955829 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipraglurant ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipraglurant IR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSR-98776 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fasoracetam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GET-73 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-14242 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-46778212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSN-2814617 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mavoglurant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAM-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize mGlu5 for Rett Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize mGluR5 for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize MGLUR5 for Anxiety Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0092273 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0431316 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0467558 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones

Featured News & Press Releases

May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-

Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD

Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD

Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-

Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome

Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents

Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder

Oct 17, 2016: Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia

Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD

Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society

Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept

Jan 04, 2016: Addex’ Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease

Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Addex Therapeutics Ltd, H1 2018

Pipeline by Aevi Genomic Medicine Inc, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by Eisai Co Ltd, H1 2018

Pipeline by Eli Lilly and Co, H1 2018

Pipeline by Heptares Therapeutics Ltd, H1 2018

Pipeline by Johnson & Johnson, H1 2018

Pipeline by Merz Pharma GmbH & Co KgaA, H1 2018

Pipeline by Novartis AG, H1 2018

Pipeline by Richter Gedeon Nyrt, H1 2018

Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

Pipeline by Toray Industries Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Discontinued Products, H1 2018

Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Addex Therapeutics Ltd
  • Aevi Genomic Medicine Inc
  • Bristol-Myers Squibb Co
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Heptares Therapeutics Ltd
  • Johnson & Johnson
  • Merz Pharma GmbH & Co KgaA
  • Novartis AG
  • Richter Gedeon Nyrt
  • Sumitomo Dainippo
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll